Clinical Scorecard: Assessment of Talquetamab in Treating Relapsed/Refractory Multiple Myeloma: Insights from an International Immunotherapy Registry Analysis

At a Glance

Key Highlights

• Talquetamab achieved an overall response rate of 74% at 0.4 mg/kg weekly dosing.

• Common adverse events include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

• Skin and nail toxicities occurred in 40% of patients, primarily mild to moderate.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of RRMM based on clinical and laboratory criteria.

Management

• Talquetamab administered as standard of care or compassionate use.

Monitoring & Follow-up

• Monitor for CRS and ICANS, grading according to established criteria.

Risks

• Patients may experience on-target, off-tumor toxicities related to GPRC5D expression.

Patient & Prescribing Data

151 patients treated with talquetamab, median age 64 years.

Patients were heavily pretreated, median of 6 prior lines of therapy.

Clinical Best Practices

• Implement supportive care measures for managing CRS and ICANS.

• Conduct regular assessments for skin and nail toxicities.

Related Resources & Content

1. Blood Cancer Journal, 2026 -- Real-World Assessment of Talquetamab for Relapsed Refractory Multiple Myeloma: A Multi-Center Study

2. FDA, 2025 -- TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

3. The ASCO Post — Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab

4. ADA News — More on Multiple Myeloma From ASCO 2023: Focus on Bispecific Antibodies

5. Blood Cancer Journal (Nature Portfolio) — Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort

6. Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab

7. More on Multiple Myeloma From ASCO 2023: Focus on Bispecific Antibodies

8. label

9. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study - ScienceDirect

10. TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

11. American Journal of Hematology | Blood Research Journal | Wiley Online Library

12. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel | Blood Cancer Journal

13. Talquetamab–Daratumumab in Relapsed or Refractory Myeloma | New England Journal of Medicine

14. Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab | New England Journal of Medicine